These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 2553830)

  • 1. Detection and incidence of neutralizing antibodies to interferon-alpha-n1.
    Weck PK; Leventhal BG; Brand C; Finter NB
    J Interferon Res; 1989 Sep; 9 Suppl 1():S37-43. PubMed ID: 2553830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser.
    Larocca AP; Leung SC; Marcus SG; Colby CB; Borden EC
    J Interferon Res; 1989 Sep; 9 Suppl 1():S51-60. PubMed ID: 2809278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3.
    Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A
    Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective.
    Spiegel RJ; Jacobs SL; Treuhaft MW
    J Interferon Res; 1989 Sep; 9 Suppl 1():S17-24. PubMed ID: 2553829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies in patients with recurrent respiratory papillomatosis treated with lymphoblastoid interferon.
    Thurmond LM; Brand CM; Leventhal BG; Finter NB; Johnston JM
    J Lab Clin Med; 1991 Sep; 118(3):232-40. PubMed ID: 1919296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High levels of circulating neutralizing antibody in normal animals to recombinant mouse interferon-beta produced in yeast.
    Sedmak JJ; Grossberg SE
    J Interferon Res; 1989 Sep; 9 Suppl 1():S61-5. PubMed ID: 2809279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
    Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
    J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alpha 2a.
    Itri LM; Sherman MI; Palleroni AV; Evans LM; Tran LL; Campion M; Chizzonite R
    J Interferon Res; 1989 Sep; 9 Suppl 1():S9-15. PubMed ID: 2681444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The influence of interferon alpha neutralizing antibodies on the therapeutic effectiveness in patients with chronic viral hepatitis].
    Tong F; Tang Y; Bai J
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Dec; 13(4):345-7. PubMed ID: 12759973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid and simple detection of IFN-neutralizing antibodies in chronic hepatitis C non-responsive to IFN-alpha.
    Jorns C; Holzinger D; Thimme R; Spangenberg HC; Weidmann M; Rasenack J; Blum HE; Haller O; Kochs G
    J Med Virol; 2006 Jan; 78(1):74-82. PubMed ID: 16299717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the immunoreactivity of anti-interferon alpha antibodies in myasthenia gravis patients. Epitope mapping.
    Bello-Rivero I; Cervantes M; Torres Y; Ferrero J; Rodríguez E; Pérez J; García I; Díaz G; López-Saura P
    J Autoimmun; 2004 Aug; 23(1):63-73. PubMed ID: 15236754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment with lymphoblastoid alpha interferon in patients with chronic myeloid leukemia refractory to recombinant interferon alpha 2].
    Steegmann JL; Granados E; Vázquez L; de la Cámara R; Peñarrubia MJ; Fernández-Contreras E; Quiroga JA; Fernández Rañada JM
    Sangre (Barc); 1998 Oct; 43(5):443-6. PubMed ID: 9868341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between in vitro and systemic effects of native and recombinant interferons-alpha on human natural killer cell cytotoxicity.
    Edwards BS; Hawkins MJ; Borden EC
    J Biol Response Mod; 1983; 2(5):409-17. PubMed ID: 6644345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors.
    Oberg K; Alm GV
    J Interferon Res; 1989 Sep; 9 Suppl 1():S45-9. PubMed ID: 2809277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of anti-interferon antibodies in the serum of chronic hepatitis C patients treated with interferon-alpha.
    Bonino F; Baldi M; Negro F; Oliveri F; Colombatto P; Bellati G; Brunetto MR
    J Interferon Cytokine Res; 1997 Jul; 17 Suppl 1():S35-8. PubMed ID: 9241614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials.
    Ernstoff MS; Fusi S; Kirkwood JM
    J Biol Response Mod; 1983; 2(6):540-7. PubMed ID: 6607324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low incidence of neutralizing antibody formation to interferon-alpha 2b in human recipients.
    Dianzani F; Antonelli G; Amicucci P; Cefaro A; Pintus C
    J Interferon Res; 1989 Sep; 9 Suppl 1():S33-6. PubMed ID: 2681442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for the presence of neutralizing antibodies against human papillomavirus type 6 in infants born to mothers with condyloma acuminata.
    Kawana K; Yasugi T; Yoshikawa H; Kawana Y; Matsumoto K; Nakagawa S; Onda T; Kikuchi A; Fujii T; Kanda T; Taketani Y
    Am J Perinatol; 2003 Jan; 20(1):11-6. PubMed ID: 12638076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-alpha antibodies in autoimmune diseases.
    Prümmer O; Seyfarth C; Scherbaum WA; Drees N; Porzsolt F
    J Interferon Res; 1989 Sep; 9 Suppl 1():S67-74. PubMed ID: 2681443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MX homologous protein in mononuclear cells from patients with systemic lupus erythematosus.
    von Wussow P; Jakschies D; Hochkeppel H; Horisberger M; Hartung K; Deicher H
    Arthritis Rheum; 1989 Jul; 32(7):914-8. PubMed ID: 2751723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.